Page 4,845«..1020..4,8444,8454,8464,847..4,8504,860..»

Stem Cell Treatment for Pets | Roger A. Mauer DVM on Channel 8 News | Las Vegas – Video

Posted: Published on October 12th, 2013

Stem Cell Treatment for Pets | Roger A. Mauer DVM on Channel 8 News | Las Vegas http://veterinary-stemcell.com Dr. Mauer is very excited to be offering Stem Cell Therapy. This innovative and affordable treatment has been making news all ... By: Roger Mauer … Continue reading →

Comments Off on Stem Cell Treatment for Pets | Roger A. Mauer DVM on Channel 8 News | Las Vegas – Video

Mesoblast Rises on Plan to Buy Stem-Cell Business: Sydney Mover

Posted: Published on October 11th, 2013

Mesoblast Ltd. (MSB) climbed the most in eight months in Sydney trading after agreeing to buy a stem-cell business of Osiris Therapeutics Inc. (OSIR) for as much as $100 million to gain new treatments. The maker of stem-cell therapies rose as much as 11 percent, the largest advance since Feb. 7, and was up 6.2 percent to A$5.82 as of 11:47 a.m. in Sydney trading. Mesoblast will buy the mesenchymal stem-cell unit of Osiris, including Prochymal, a treatment for acute graft versus host disease, Columbia, Maryland-based Osiris said in a statement. The price tag includes as much as $50 million in payments if certain trial and regulatory milestones are met, and Osiris may also receive royalties on sales of certain products, Melbourne-based Mesoblast said in a separate statement today. Prochymal has received conditional approval in Canada and New Zealand for use in children with acute graft versus host disease, and is available under an access program in the U.S. for treating both children and adults, according to Osiriss statement. The illness is a complication that can occur after a stem-cell or bone-marrow transplant in which the newly transplanted donor cells attack the transplant recipients body, according to Medline Plus. To … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mesoblast Rises on Plan to Buy Stem-Cell Business: Sydney Mover

Mesoblast's US patents deal lifts shares

Posted: Published on October 11th, 2013

Silviu Itescu. Shares in stem cell group Mesoblast surged to two-month highs on its decision on Friday to outlay up to $US100 million to buy a suite of patents in the US that hold the potential to deliver revenues sooner than expected. In a deal with US-based Osiris Therapeutic for an initial $US20 million in cash, along with further future payments, Mesoblast is to gain access to two products in their final stage of clinical trials which already hold approvals for sale in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. ''These are substantially derisked,'' Mesoblast chief executive Silviu Itescu said of the two advanced products, an agent for treating some Crohn's disease cases along with a treatment for bone marrow cases resulting from stem cell transplants. Mesoblast shares closed up 4.7 per cent on Friday at $5.74. Advertisement Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells that can help body tissue heal large wounds and repair cartilage and muscle tissue. Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan. … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mesoblast's US patents deal lifts shares

Mesoblast to aquire further stem cell assets

Posted: Published on October 11th, 2013

Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected. Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well. The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants. Advertisement In afternoon trading, the shares were up 5.1 per cent at $5.76. Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mesoblast to aquire further stem cell assets

Mesoblast jumps on stem cell asset purchase

Posted: Published on October 11th, 2013

Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected. Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well. The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants. Advertisement In afternoon trading, the shares were up 5.1 per cent at $5.76. Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Mesoblast jumps on stem cell asset purchase

Kill takes leave to focus on Epilepsy treatment

Posted: Published on October 11th, 2013

Minneapolis, MN (SportsNetwork.com) - Minnesota director of athletics Norwood Teague announced Thursday that head football coach Jerry Kill is taking time away from the team to focus on his Epilepsy treatment. Kill suffered his fifth seizure-related episode since taking the job at Minnesota in 2011 prior to the team's Oct. 5 loss at Michigan. "My wife Rebecca, myself and our two daughters want to thank everyone for their prayers and concerns during the last few weeks," Kill said in statement released by the school Thursday. "This was a difficult decision to make, but the right decision. Every decision that will be made will be in the best interest of the players and the program. I look forward to returning to the Minnesota sideline on a full-time basis soon." Defensive coordinator Tracy Claeys served as Minnesota's acting head coach in the setback against Michigan and will continue in that role while Kill is away. "Coach Kill is taking time to continue treatment and focus on managing his Epilepsy," Teague said. "Tracy Claeys will serve as the interim head coach until Coach Kill is ready to return. Coach Kill will remain in very close contact with the team and his staff and … Continue reading →

Comments Off on Kill takes leave to focus on Epilepsy treatment

American Epilepsy Society's Announces 67th Annual Meeting

Posted: Published on October 11th, 2013

Newswise West Hartford, October 10, 2013 The American Epilepsy Society (AES) has announced that registration is now open for its 67th Annual Meeting, December 6 10, 2013, at the Washington, D.C., Convention Center. The Washington conference will feature more than 1,000 scientific posters and platform reports, in addition to diverse educational courses, symposia, special interest group sessions, and workshops on the clinical care and scientific understanding of seizures and epilepsy. Offerings for professionals in the board certified sub-specialty of epileptology and related healthcare providers will include: A one-day course on An Algorithmic Approach to the Diagnosis and Treatment of Non-Lesional Epilepsy; A fundamentals of epilepsy symposium on Neuroimaging in Epilepsy with a focus on standard and novel neuroimaging techniques in the evaluation of epilepsy; An epilepsy specialist symposium on Treating the New Onset Epilepsy Patient; Skills Workshops Sessions; Sessions on the Changing Landscape of Epilepsy Surgery, Future of Treating, Preventing and Curing Epilepsy in the Year 2025 and Neuropsychology: Epilepsy and the Aging Brain. The AES annual scientific and educational meeting attracts the participation of more than 4,000 physicians, scientists, and allied healthcare professionals from around the world. Additional conference program information, registration instructions, and other details are available on … Continue reading →

Comments Off on American Epilepsy Society's Announces 67th Annual Meeting

Minnesota's Kill steps away for treatment

Posted: Published on October 11th, 2013

Minneapolis, MN (SportsNetwork.com) - Minnesota football coach Jerry Kill is taking time away from the team to focus on his epilepsy treatment, Golden Gophers athletic director Norwood Teague announced Thursday. Kill suffered his fifth seizure-related episode since taking the job at Minnesota in 2011 prior to the team's Oct. 5 loss at Michigan. "My wife Rebecca, myself and our two daughters want to thank everyone for their prayers and concerns during the last few weeks," Kill said in statement. "This was a difficult decision to make, but the right decision. Every decision that will be made will be in the best interest of the players and the program. I look forward to returning to the Minnesota sideline on a full-time basis soon." Defensive coordinator Tracy Claeys served as Minnesota's acting head coach against Michigan and will continue in that role while Kill is away. "Coach Kill is taking time to continue treatment and focus on managing his Epilepsy," Teague said. "Tracy Claeys will serve as the interim head coach until coach Kill is ready to return. Coach Kill will remain in very close contact with the team and his staff and provide direction and support as needed. Our support for … Continue reading →

Comments Off on Minnesota's Kill steps away for treatment

Minnesota Coach Jerry Kill on Leave for Epilepsy

Posted: Published on October 11th, 2013

Even as his seizures have grown in frequency over the last two years, Minnesota coach Jerry Kill has always maintained that his epilepsy would never slow him down. When he wasn't able to make it to a game for the first time in his coaching career last weekend against Michigan, Kill decided it was time to take a step back, put his health before football for once and try to get a handle on an issue that has taken him from the sideline twice in the last month. Kill and the university announced Thursday that the coach is taking an open-ended leave of absence from the team to focus on treatment and management of his epilepsy, and it is uncertain when he will be able to return to the Golden Gophers. "This was a difficult decision to make, but the right decision," Kill said in a statement distributed by the university. "Our staff has been together a long time and I have full confidence in coach Claeys and them during my time away. Every decision that will be made will be in the best interest of the players and the program. I look forward to returning to the Minnesota sideline … Continue reading →

Comments Off on Minnesota Coach Jerry Kill on Leave for Epilepsy

Minnesota HC Kill to focus on Epilepsy treatment

Posted: Published on October 11th, 2013

Minneapolis, MN (SportsNetwork.com) - Minnesota director of athletics Norwood Teague announced Thursday that head football coach Jerry Kill is taking time away from the team to focus on his Epilepsy treatment. Kill suffered his fifth seizure-related episode since taking the job at Minnesota in 2011 prior to the team's Oct. 5 loss at Michigan. "My wife Rebecca, myself and our two daughters want to thank everyone for their prayers and concerns during the last few weeks," Kill said in statement released by the school Thursday. "This was a difficult decision to make, but the right decision. Every decision that will be made will be in the best interest of the players and the program. I look forward to returning to the Minnesota sideline on a full-time basis soon." Defensive coordinator Tracy Claeys served as Minnesota's acting head coach in the setback against Michigan and will continue in that role while Kill is away. "Coach Kill is taking time to continue treatment and focus on managing his Epilepsy," Teague said. "Tracy Claeys will serve as the interim head coach until Coach Kill is ready to return. Coach Kill will remain in very close contact with the team and his staff and … Continue reading →

Comments Off on Minnesota HC Kill to focus on Epilepsy treatment

Page 4,845«..1020..4,8444,8454,8464,847..4,8504,860..»